Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FX-111 in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT07719361 is registered in ClinicalTrials.gov with Flare Therapeutics Inc. as lead sponsor.

NCT NCT07719361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07719361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FX-111 in Patients With Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Flare Therapeutics Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
July 1, 2026
Completion date
February 15, 2029
Enrollment
60 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

mcrpc, mcrpc (metastatic castration-resistant prostate cancer), mcrpc or advanced/metastatic solid tumors, mcrpc, metastatic castration resistant prostate cancer, metastatic castration resistant prostate cancer, neoplasms of prostate, neoplasms prostate, prostatic neoplasms, prostatic neoplasms, castration-resistant